ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AHCO vs STLN // RETURN ON INVESTED CAPITAL (ROIC)

AdaptHealth Corp. (NASDAQ) VS. Starling Oncology Inc. (NASDAQ) • 15-METRIC TALLY: AHCO 4 — STLN 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: AHCO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AHCO VS. STLN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AHCO STLN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 18.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE 2.20% -35.00% +37.20 AHCO /roic <GO>
EV/EBITDA & P/E Valuation 6.1x — — TIE /valuation <GO>
Free Cash Flow Yield — -4.10% — TIE /fcf-yield <GO>
Operating Margin 2.80% -7.20% +10.00 AHCO /operating-margins <GO>
Net Profit Margin -2.20% 68.00% -70.20 STLN /net-margins <GO>
Revenue Growth (YoY) -0.50% 27.80% -28.30 STLN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.79 2.58 -1.79 STLN /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 AHCO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.1 51.8 -3.70 STLN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $808.5M $677.7M $130.8M AHCO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AHCO REV STLN REV AHCO GROSS % STLN GROSS % AHCO FCF STLN FCF
FY 2025 $3.24B $502.7M 18.8% — $219.4M -$27.8M
FY 2024 $3.26B $393.4M 20.9% — $235.8M -$30.3M
FY 2023 $3.20B $324.2M — — $480.7M -$36.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AHCO // BETA —
STLN // BETA —